What I write about, and why
A short note on the difference between the Articles section and this one, and what I am trying to be useful about.
Two sections here, deliberately.
Articles are the longer pieces — a guidance I have read closely, an enforcement pattern worth naming, a question I think quality units should be able to answer before somebody asks them in a conference room.
Blog is shorter. Observations, reactions, the occasional thing that made me put my coffee down.
The thread running through both
I spent eight years at FDA. I led GMP inspections of small molecules, biologics and combination products, domestically and abroad. I now work on the other side of that table.
That gives me one useful habit: I tend to ask what an investigator would actually see, rather than what a procedure says should be visible. Those are not the same question, and the distance between them is where most findings live.
So when I write about a guidance, I am usually asking the same few things:
- What is the expectation, stated plainly?
- Where is it ambiguous, and what will companies do in response to that ambiguity?
- What does it look like on a shop floor, in a document room, under questioning?
What you will not find here
Client names. Product names. Anything from an engagement that is not mine to tell.
Everything I write about public guidance, public enforcement and public filings is fair game and openly sourced. Everything else stays where it belongs.
If something here is wrong, I would genuinely like to know. My email is on the contact page.